Literature DB >> 17647094

Hereditary neoplasia syndromes and the role of the surgeon.

Lisa C Coviello1, Robert A Wascher.   

Abstract

The complex and often variable clinical presentations of patients with hereditary neoplasia syndromes mandates a multidisciplinary approach to management. The involvement of surgeons in the assessment and management of these patients is essential, in that the majority of patients affected with hereditary neoplasms will, at some point, require resection of the target organs affected by specific gene mutations, with prophylactic or therapeutic intent, or both. As the pathogenesis of the known hereditary neoplasia syndromes becomes better understood at the molecular level, innovative targeted therapies will, inevitably, supplant or replace surgery as the primary treatment modality for these diseases. Until that time, however, surgeons will continue to play a prominent role in the care of patients with hereditary neoplasia syndromes. As is already occurring within many other clinical specialties, the incorporation of at least a basic understanding of the genetic mechanisms of disease transmission and expression are essential within the surgical specialties, as the two cases presented herein demonstrate. In this paper, we present two cases that illustrate many of the challenges inherent in the surgical management of patients with hereditary neoplasia syndromes: a patient with attenuated familial adenomatous polyposis syndrome, and a patient with multiple endocrine neoplasia syndrome, type 2-B.

Entities:  

Mesh:

Year:  2007        PMID: 17647094     DOI: 10.1007/s10689-007-9156-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  9 in total

1.  The Asp1822Val variant of the APC gene is a common polymorphism without clinical implications.

Authors:  C Ruiz-Ponte; A Vega; R Conde; F Barros; A Carracedo
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

2.  Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer.

Authors:  C Ruiz-Ponte; A Vega; A Carracedo; F Barros
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

3.  APC Asp1822Val and Gly2502Ser polymorphisms and risk of colorectal cancer and adenoma.

Authors:  Gregory J Tranah; Edward Giovannucci; Jing Ma; Charles Fuchs; David J Hunter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

4.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

Review 5.  Highly penetrant hereditary cancer syndromes.

Authors:  Rebecca Nagy; Kevin Sweet; Charis Eng
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

6.  Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes.

Authors:  T C Lairmore; D W Ball; S B Baylin; S A Wells
Journal:  Ann Surg       Date:  1993-06       Impact factor: 12.969

7.  Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition.

Authors:  Y L Wallis; D G Morton; C M McKeown; F Macdonald
Journal:  J Med Genet       Date:  1999-01       Impact factor: 6.318

8.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

Authors:  C Eng; D P Smith; L M Mulligan; M A Nagai; C S Healey; M A Ponder; E Gardner; G F Scheumann; C E Jackson; A Tunnacliffe
Journal:  Hum Mol Genet       Date:  1994-02       Impact factor: 6.150

Review 9.  The concise handbook of family cancer syndromes. Mayo Familial Cancer Program.

Authors:  N M Lindor; M H Greene
Journal:  J Natl Cancer Inst       Date:  1998-07-15       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.